Synthesis and biological activity of enantiomeric pairs of 5-(alk-2-enyl)thiolactomycin and 5-[(E)-cycloalk-2-enylidenemethyl] thiolactomycin congeners

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 9, 2009, Pages 920-936

  Ohata, Kohei ^a   Terashima, Shiro ^b  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b SAGAMI CHEMICAL RESEARCH CENTER   (Japan)

Author keywords

5 (alk 2 enyl) thiolactomycin; 5 (E) cycloalk 2 enylidenemethyl thiolactomycin; Thiolactomycin; Type I fatty acid synthase inhibitor

Indexed keywords

5 (ALK 2 ENYL)THIOLACTOMYCIN; 5 [CYCLOALK 2 ENYLIDENE METHYL]THIOLACTOMYCIN; FATTY ACID SYNTHASE INHIBITOR; THIOLACTOMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN HEPG2; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IC 50; MYCOBACTERIUM TUBERCULOSIS; NOCARDIA; PLASMODIUM; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; FATTY ACID SYNTHESIS INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 70349182343     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.920     Document Type: Article

References (43)

1. Ohata K., Terashima S., Bioorg. Med. Chem. Lett., 17, 4070-4074 (2007).
2. Ohata K., Terashima S., Bioorg. Med. Chem. Lett., 18, 5598-5600 (2008).
3. Oishi H., Noto T., Sasaki H., Suzuki K., Hayashi T., Okazaki H., Ando K., Sawada M., J. Antibiot., 35, 391-395 (1982).
4. Noto T., Miyakawa S., Oishi H., Endo H., Okazaki H., J. Antibiot., 35, 401-410 (1982).
5. Miyakawa S., Suzuki K., Noto T., Harada Y., Okazaki H., J. Antibiot., 35, 411-419 (1982).
6. Kremer L., Douglas J. D., Baulard A. R., Morehouse C., Guy M. R., Alland D., Dover L. G., Lakey J. H., Jacobs W. R., Brennan P. J., Minnikin D. E., Besra G. S., J. Biol. Chem., 275, 16857-16864 (2000).
7. Slayden R. A., Lee R. E., Armour J. W., Cooper A. M., Orme I. M., Brennan P. J., Besra G. S., Antimicrob. Agents Chemother., 40, 2813-2819 (1996).
8. Waller R. F., Ralph S. A., Reed M. B., Su V., Douglas J. D., Minnikin D. E., Cowman A. F., Besra G. S., McFadden G. I., Antimicrob. Agents Chemother., 47, 297-301 (2003).
9. Jones S. M., Urch J. E., Brun R., Harwood J. L., Berry C., Gilber I. H., Bioorg. Med. Chem., 12, 683-692 (2004).
10. Jackowski S., Murphy C. M., Cronan J. E., Rock C. O., J. Biol. Chem., 264, 7624-7629 (1989).
11. Price A. C., Choi K.-H., Heath R. J., Li Z., White S. W., Rock C. O., J. Biol. Chem., 276, 6551-6559 (2001).
12. Hayashi T., Yamamoto O., Sasaki H., Kawaguchi A., Okazaki H., Biochem. Biophys. Res. Commun., 115, 1108-1113 (1983).
13. Nishida I., Kawaguchi A., Yamada M., J. Biochem. (Tokyo), 99, 1447-1454 (1986).
14. Jones A. L., Herbert D., Rutter A. J., Dancer J. E., Harwood J. L., Biochem. J., 347, 205-209 (2000).
15. McFadden J. M., Medghalchi S. M., Thupari J. N., Pinn M. L., Vadlamudi A., Miller K. I., Kuhajda F. P., Townsend C. A., J. Med. Chem., 48, 946-961 (2005).
16. Sakya S. M., Suarez-Contreras M., Dirlam J. P., O'Connell T. N., Hayashi S. F., Santoro S. L., Kamicker B. J., George D. M., Ziegler C. B., Bioorg. Med. Chem. Lett., 11, 2751-2754 (2001).
17. Kim P., Zhang Y.-M., Shenoy G., Nguyen Q.-A., Boshoff H. I., Manjunatha U. H., Goodwin M. B., Lonsdale J., Price A. C., Miller D. J., Duncan K., White S. W., Rock C. O., Barry C. E. III, Dowd C. S., J. Med. Chem., 49, 159-171 (2006).
18. Senior S. J., Illarionov P. A., Gurcha S. S., Campbell I. B., Schaeffer M. L., Minnikin D. E., Besra G. S., Bioorg. Med. Chem. Lett., 13, 3685-3688 (2003).
19. Senior S. J., Illarionov P. A., Gurcha S. S., Campbell I. B., Schaeffer M. L., Minnikin D. E., Besra G. S., Bioorg. Med. Chem. Lett., 14, 373-376 (2004).
20. Kamal A., Shaik A. A., Sinha R., Yadav J. S., Arora S. K., Bioorg. Med. Chem. Lett., 15, 1927-1929 (2005).
21. Jones S. M., Urch J. E., Kaiser M., Brun R., Harwood J. L., Berry C., Gilbert I. H., J. Med. Chem., 48, 5932-5941 (2005).
22. Chambers M. S., Thomas E. J., J. Chem. Soc., Perkin Trans. 1, 1997, 417-431 (1997).
23. McFadden J. M., Frehywot G. L., Townsend C. A., Org. Lett., 4, 3859-3862 (2002).
24. Toyama K., Tanchi T., Mase N., Yoda H., Takabe K., Tetrahedron Lett., 47, 7163-7166 (2006).
25. Dormann K. L., Brückner R., Angew. Chem., Int. Ed., 46, 1160-1163 (2007).
26. Ohata K., Terashima S., Tetrahedron Lett., 47, 2787-2791 (2006).
27. Ohata K., Terashima S., Tetrahedron, 65, 2244-2253 (2009).
28. In addition to 5a-c, 6a-c and their enantiomers (ent-5a-c, ent-6a-c), 5-[(E)-cyclopent-2-enylidenemethyl]-TLM, its 3-demethyl congener and their enantiomers (5d, 6d, ent-5d, ent-6d) were designed and their synthesis was attempted following the same synthetic scheme shown in Chart 2. Although the scheme proceeded smoothly to the stage of 20 (n=0), aldehyde 21 (n=0) derived from 20 (n=0) was found to be very unstable, probably due to facile isomerization to the cyclopentadiene derivative and the subsequent intramolecular Diels-Alder reaction (Ohata K. and Terashima S., unpublished results).
29. Kuhajda F. P., Pizer E. S., Li J. N., Mani S., Frehywot G. L., Townsend C. A., Proc. Natl. Acad. Sci. U.S.A., 97, 3450-3454 (2000).
30. Ho G. J., Mathre P. J., J. Org. Chem., 60, 2271-2273 (1995).
31. 1H-NMR spectrum, the two olefinic protons of 11b showed larger chemical shifts than 24b. The same relationships were also observed for the chemical shift values of 11a, c-f and 24a, c-f.
32. Seebach D., Hungerbuhler E., Naef R., Schurrenberger P., Weidmann B., Zuger M., Synthesis, 1982, 138-141 (1982).
33. Evans D. A., Britton T. C., Ellman J. A., Dorow R. L., J. Am. Chem. Soc., 112, 4011-4030 (1990).
34. Tamura R., Sato M., Oda D., J. Org. Chem., 51, 4368-4375 (1986).
35. Naya A., Ishikawa M., Matsuda K., Ohwaki K., Saeki T., Noguchi K., Ohtake N., Bioorg. Med. Chem., 11, 875-884 (2003).
36. In the absence of HMPA, the deconjugative asymmetric α- sulfenylation of 19a did not take place at all.
37. 1H-NMR spectrum and/or HPLC analysis are as follows: 19/26/27; 12 : 2 : 1 for 19a/26a/27a; 14 : 1 : 4 for 19b/26b/27b; 12 : 1 : 1 for 19c/26c/27c.
38. 3): 5.44 ppm [(Me)(SR)C-CH=C] for 19a; 5.50 ppm [(Me)(SR)C-CH=C] for the (S)-diastereomer of 19a (26a); 5.56 ppm [(Me)(SR)C-CH=C] for 19b; 5.62 ppm [(Me)(SR)C-CH=C] for the (S)-diastereomer of 19b (26b); 5.64 ppm [(Me)(SR)C-CH=C] for 19c; 5.72 ppm [(Me)(SR)C-CH=C] for the (S)-diastereomer of 19c (26c); 5.72 ppm [(Me)(SR)C-CH=C] for the synthetic intermediate of 1; 5.77 ppm [(Me)(SR)C-CH=C] for the (S)-diastereomer of the synthetic intermediate of 1.
39. The enantiomeric exesses of 3a-f, ent-3a-f, 4a-f, ent-4a-f, 5a-c, ent-5a-c, 6a-c and ent-6a-c were shown in Table 3 and in Experimental.
40. Determination of MICs by agar dilution methods was performed according to the guideline M7-A6 of the Clinical and Laboratory Standards Institute (2003).
41. 14C] acetate into cellular fatty acid as previously described with some modifications. See, Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., Kadowaki T., Diabetes, 47, 1841-1847 (1998).
42. Formation of two types of the by-products corresponding to 24b and 25b was observed, similar to the case described for the preparation of 11b, 24b and 25b from 9b.
43. D α values for those compounds were not included in this report. At present, the reason for the observed inconsistency is unclear.